Author/Editor		Karrer, K; Denck, H; Karnicka-Mlodkowska, H; Drings, P; Orel, J; Salzer, GM; Thermann, M; Lattuneddu, A; Sun, Y; Hata, E
Title		The role of ifosfamide and cyclophosphamide in the multi-modality treatment after surgery for cure for small-cell bronchial carcinomas (SCLC)
Type		članek
Source		Med Oncol Tumor Pharmacother
Vol. and No.		Letnik 6, št. 2
Publication year		1989
Volume		str. 143-9
Language		eng
Abstract		For the optimisation of the therapy for small cell bronchial carcinomas (SCLC), surgery is used to eliminate the primary tumor and its regional lymph nodes and chemo- and radiotherapy for the general treatment of micrometastasis. After patho-histological examination of the operation specimen, randomization for two arms is performed for a standard chemotherapy (CAV) or a sequential chemotherapy using three different drug combinations. Thereafter all disease-free patients receive prophylactic cranial irradiation (PCI). Preliminary evaluations in December 1987, of 112 patients from 19 cooperating departments show that the survival rate projected for 2 yr of 43 patients at stage pT1-3 N0 M0 is 76 percent, of 43 patients at stage pT1-3 N1 M0 it is 63 percent and of 26 patients at stage pT1-3 N2 M0 it is 38 percent.
Descriptors		ANTINEOPLASTIC AGENTS, COMBINED BRONCHIAL NEOPLASMS CARCINOMA, SMALL CELL COMBINED MODALITY THERAPY CYCLOPHOSPHAMIDE FOLLOW-UP STUDIES IFOSFAMIDE MULTICENTER STUDIES POSTOPERATIVE CARE RANDOM ALLOCATION